3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
14
Urogenital Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Bulbo-Spinal Atrophy, X-Linked
1
Adenocarcinoma
1
Interventions
enzalutamide
2
Prednisone
2
Abiraterone Acetate
2
tasquinimod
1
sabizabulin
1
niraparib
1
darolutamide
1
atezolizumab
1
abiraterone
1
Radiosurgery
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms, Castration-Resistant
×
abiraterone
×
Clear all
NCT04844749
2024-02-05
VERACITY
Veru Inc.
Phase 3
Terminated
105 enrolled